161 related articles for article (PubMed ID: 11948496)
1. Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations.
Geertsen R; Böni R; Blasczyk R; Romero P; Betts D; Rimoldi D; Hong X; Laine E; Willers J; Dummer R
Int J Cancer; 2002 May; 99(1):82-7. PubMed ID: 11948496
[TBL] [Abstract][Full Text] [Related]
2. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
3. High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Rodriguez T; Méndez R; Roberts CH; Ruiz-Cabello F; Dodi IA; López Nevot MA; Paco L; Maleno I; Marsh SG; Pawelec G; Garrido F
Cancer Immunol Immunother; 2005 Feb; 54(2):141-8. PubMed ID: 15592718
[TBL] [Abstract][Full Text] [Related]
4. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
Rivoltini L; Barracchini KC; Viggiano V; Kawakami Y; Smith A; Mixon A; Restifo NP; Topalian SL; Simonis TB; Rosenberg SA
Cancer Res; 1995 Jul; 55(14):3149-57. PubMed ID: 7541714
[TBL] [Abstract][Full Text] [Related]
5. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
6. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F
Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29.
Wang Z; Seliger B; Mike N; Momburg F; Knuth A; Ferrone S
Cancer Res; 1998 May; 58(10):2149-57. PubMed ID: 9605759
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele.
Real LM; Jimenez P; Cantón J; Kirkin A; García A; Abril E; Zeuthen J; Ruiz-Cabello F; Garrido F
Int J Cancer; 1998 Jan; 75(2):317-23. PubMed ID: 9462725
[TBL] [Abstract][Full Text] [Related]
9. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
10. Isolation and molecular characterization of spontaneous mutants of lymphoblastoid cells with extended loss of heterozygosity.
de Nooij-van Dalen AG; van Buuren-van Seggelen VH; Mulder A; Gelsthorpe K; Cole J; Lohman PH; Giphart-Gassler M
Mutat Res; 1997 Mar; 374(1):51-62. PubMed ID: 9067415
[TBL] [Abstract][Full Text] [Related]
11. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.
Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF
J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
[TBL] [Abstract][Full Text] [Related]
13. Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression.
Willers J; Urosevic M; Laine E; Geertsen R; Kündig T; Burg G; Dummer R
J Invest Dermatol; 2001 Dec; 117(6):1498-504. PubMed ID: 11886514
[TBL] [Abstract][Full Text] [Related]
14. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
15. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.
Wang Z; Marincola FM; Rivoltini L; Parmiani G; Ferrone S
J Exp Med; 1999 Jul; 190(2):205-15. PubMed ID: 10432284
[TBL] [Abstract][Full Text] [Related]
16. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
[TBL] [Abstract][Full Text] [Related]
17. Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy.
Mendez R; Serrano A; Jäger E; Maleno I; Ruiz-Cabello F; Knuth A; Garrido F
Tissue Antigens; 2001 Jun; 57(6):508-19. PubMed ID: 11556981
[TBL] [Abstract][Full Text] [Related]
18. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA
J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379
[TBL] [Abstract][Full Text] [Related]
19. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL).
Wölfel T; Hauer M; Klehmann E; Brichard V; Ackermann B; Knuth A; Boon T; Meyer Zum Büschenfelde KH
Int J Cancer; 1993 Sep; 55(2):237-44. PubMed ID: 7690346
[TBL] [Abstract][Full Text] [Related]
20. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
